Anti-CTGF 抗体
Anti-CTGF antibody
4
(29 Reviews)
|
(379 Publications)
Anti-CTGF antibody (ab6992) is a rabbit polyclonal antibody detecting CTGF in Western Blot, IP, IHC-P, IHC-Fr, ICC/IF. Suitable for Human, Mouse, Rat, Sheep.
- Over 310 publications
- Trusted since 2001
別名を表示する
CTGF, HCS24, IGFBP8, CCN2, CCN family member 2, Cellular communication network factor 2, Connective tissue growth factor, Hypertrophic chondrocyte-specific protein 24, Insulin-like growth factor-binding protein 8, IBP-8, IGF-binding protein 8, IGFBP-8
- IHC-Fr
CiteAb
Immunohistochemistry (Frozen sections) - Anti-CTGF antibody (AB6992)
CTGF Immunohistochemistry-immunofluorescence using Anti-CTGF antibody ab6992. Publication image and figure legend from Li, C., Zhen, G., et al., 2016, Nat Commun, PubMed 27126736.
Activation of RhoA promotes CTGF-VEGF complex formation in ECM, whereas inactivation of RhoA induces MMP3-mediated CTGF cleavage and VEGF release.(a-d) Immunofluorescence analysis of the binding of VEGF to ECM in different MSC cultures. MSCs were incubated with the indicated treatments for 7 days. Immunofluorescence staining was performed on non-permeabilized cells using antibodies against CTGF (a), fibronectin (b), collagen I (c) or VEGF (d). (e,f) MSCs were transfected with siRNA-control or siRNA-CTGF, then cultured with the indicated medium for 6 days. Western blot (WB) analysis of the cell lysates was performed using antibodies against CTGF and β-actin (e). Immunofluorescence staining was performed on non-permeabilized cells using antibodies against CTGF or VEGF (f). (g-j) WB and co-immunoprecipitation (IP) analyses of VEGF and CTGF in the overlay media of MSCs with different treatment. MSCs were incubated with the indicated treatments for 7 days. Overlay media : M1, M2, M3 and M4 were collected, respectively. Western blotting analysis of the overlay media was performed using antibodies against CTGF (g), MMP3 (h) and VEGF (i). Overlay media were subjected to IP assays using antibody against VEGF, the VEGF-associated CTGF was detected by western blotting with antibody against CTGF (j). (k,l) WB analysis of VEGF and CTGF in the ECMs of the cultured MSCs with different treatment. MSCs were incubated with the indicated treatment for 7 days. ECMs : E1, E2, E3 and E4 were collected. Western blotting analysis of the ECMs was performed using antibodies against CTGF (k) and VEGF (l). (m-o) WB and co-IP analysis of VEGF and CTGF in the overlay media of MSCs transfected with empty vector (EV) or L63RhoA. In the aliquots of the overlay medium collected from the cells overexpressed L63RhoA, 50 or 100 ng ml-1 rMMP3 was added and the reactions were maintained at 37 °C for 2 h. Overlay media were subjected to immunoprecipitation assays using antibody against VEGF, the VEGF-associated CTGF was detected by western blotting with antibody against CTGF (m). Western blotting analysis of the overlay media was performed using antibodies against CTGF (n) and MMP3 (o). Scale bars, 50 μm. Data are representative of three independent experiments.
- WB
CiteAb
Western blot - Anti-CTGF antibody (AB6992)
CTGF western blot using Anti-CTGF antibody ab6992. Publication image and figure legend from Choi, S. Y., Bae, H., et al., 2020, Nat Commun, PubMed 31980640.
FRC-specific depletion of Ltbr activates YAP/TAZ-induced myofibrosis.a Diagram for generation of indicated mice and their analyses at 8-weeks old. b Representative images and comparisons of indicated marker expressions on CCL19-YFP+ FRCs in WTΔFRC-YR and LtbrΔFRC-YR mice. Scale bars, 20 µm. c Representative images and comparisons of YAP and TAZ nuclear localization (white arrows) in inguinal LN of WTΔFRC and LtbrΔFRC mice. Scale bars, 20 µm. d Comparison of indicated mRNA expression in FRCs sorted from WTΔFRC and LtbrΔFRC mice. Each dot indicates a mean of quadruplicate values using n = 8-12 mice/group from three independent experiments. e Diagram for primary culture of FRCs derived from i-Lats1/2ΔFRC-TR mice and treatment with EtOH (control) or 4-OHT at 4 days after the culture and their analyses at 2 days after the treatment. f Immunoblot analysis of indicated proteins in primary cultured mouse FRCs after treatment with EtOH or 4-OHT for 2 days. g Comparisons of indicated mRNA expression normalized to Gapdh in primary cultured mouse FRCs after treatment with EtOH or 4-OHT for 2 days. Each dot indicates a mean of triplicate values from three independent experiments. h, i Representative images and comparisons of indicated marker expressions in primary cultured mouse FRCs after treatment with EtOH or 4-OHT for 2 days. Scale bars, 30 μm. Each dot indicates a mean of triplicate values from three independent experiments. j Diagram for primary culture of human FRCs for 4 days and infection with an adenovirus to induce overexpression of active YAP (YAP5SA) or TAZ (TAZ4SA) for their analyses at 2 days after the infection. k, l Representative images and comparisons of indicated marker expressions in primary cultured human FRCs infected with control-, YAP5SA-, or TAZ4SA-adenovirus. Scale bars, 30 μm. Each dot indicates a mean of triplicate values from three independent experiments. Unless otherwise denoted, each dot indicates a value obtained from one mouse and n = 5 mice/group pooled from two independent experiments. Horizontal bars indicate mean ± SD and P values versus WTΔFRC or WTΔFRC-YRby two-tailed Mann-Whitney U test except for (g), (i), and (l) (two-tailed Student's t-test). NS, not significant.
false
- WB
CiteAb
Western blot - Anti-CTGF antibody (AB6992)
CTFG western Blot using Anti-CTGF antibody ab6992. Publication image and figure legend from Cheong, M. L., Lai, T. H., et al. 2019, PLoS One PubMed 30695033.
Effects of TGFβ isoforms on collagen and CTGF protein and mRNA expression in HESCs.(A) Cells were treated with the indicated concentration of TGFβ1 for 16 h and then analyzed through Western blotting (n = 3). (B) Effect of TGFβ isoforms on collagen and CTGF mRNA expression in HESCs. Cells were treated with vehicle or TGFβ isoforms (ng/ml) for 4 h. The mRNA expression level of collagen, CTGF, and β-actin was analyzed through RT-PCR and densitometry (n = 2). *p < < 0.05, **p < < 0.01, and ***p < < 0.001 versus vehicle treatment only (basal).
false
Reactivity data
製品の詳細
Anti-CTGF antibody (ab6992) is a rabbit polyclonal antibody and is validated for use in ICC/IF, IHC-FoFr, IHC-Fr, IHC-P, IP, WB in human, mouse, rat, sheep samples.
Anti-CTGF antibody (ab6992) specifically detects CTGF (UniProt ID: P29268; Molecular weight: 35kDa) and is sold in 50 µg selling sizes.
Quality and Validation
Abcam's high quality validation processes ensure Anti-CTGF antibody (ab6992) has high sensitivity and specificity.
Anti-CTGF antibody (ab6992) has been cited over 313 times in peer reviewed journals and is trusted by the scientific community.
Anti-CTGF antibody (ab6992) has 28 independent reviews from customers.
Target Information
Connective Tissue Growth Factor (CTGF), also known as CCN2 is a protein that regulates various biological process including cell proliferation and migration. CTGF influences the tumor microenvironment by promoting angiogenesis, inflammation, and activation of cancer-associated fibroblasts (CAFs). Elevated levels of CTGF have been observed in several cancers, such as pancreatic, breast, and liver cancers.
出荷温度及び保存条件
製品の状態
精製方法
バッファー組成
出荷温度
短期保存期間
短期保存温度
長期保存温度
分注に関する情報
保管に関する情報
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Connective Tissue Growth Factor plays an important role in cell adhesion proliferation and differentiation. It operates as an independent protein but can also be part of the extracellular matrix structure. CTGF functions as a mediator in the interaction between cells and their surrounding environment influencing processes such as angiogenesis and wound healing through these interactions.
Pathways
CTGF fits into the TGF-beta and Wnt signaling pathways where it helps modulate cellular responses to external stimuli. It interacts with proteins like fibronectin and integrins within these pathways enhancing cellular communication and response. These pathways are fundamental for both development and pathological conditions showing CTGF's influence on various biological processes.
製品プロトコール
- Visit the General protocols
- Visit the Troubleshooting
ターゲットの情報
文献 (379)
Recent publications for all applications. Explore the full list and refine your search
Physiological reports 13:e70546 PubMed40969144
2025
Applications
Unspecified application
Species
Unspecified reactive species
iScience 28:112608 PubMed40502710
2025
Applications
Unspecified application
Species
Unspecified reactive species
Materials today. Bio 32:101757 PubMed40290884
2025
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 26: PubMed40243677
2025
Applications
Unspecified application
Species
Unspecified reactive species
JCI insight 10: PubMed40232859
2025
Applications
Unspecified application
Species
Unspecified reactive species
African health sciences 24:276-285 PubMed40190527
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 16:3251 PubMed40185752
2025
Applications
Unspecified application
Species
Unspecified reactive species
British journal of pharmacology 182:2560-2581 PubMed39965654
2025
Applications
Unspecified application
Species
Unspecified reactive species
Clinical and translational medicine 15:e70189 PubMed39956959
2025
Applications
Unspecified application
Species
Unspecified reactive species
Respiratory research 26:51 PubMed39939959
2025
Applications
Unspecified application
Species
Unspecified reactive species
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com